Gemcitabine +/- Imatinib Mesylate, Patients w/Previously Treated Metastatic Breast Cancer
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: gemcitabine hydrochloride|DRUG: imatinib mesylate
Sponsor: Rutgers, The State University of New Jersey
Collaborators: National Cancer Institute (NCI)|Novartis Pharmaceuticals|Rutgers Cancer Institute of New Jersey